Real Life Report





This report is intended to be a rallying cry to the wider financial community to support the UK’s Healthcare and Life Sciences sectors. The UK’s leading life science and healthcare company CEOs, leading investors, banks and stakeholders such as Rt Hon. George Freeman, Neil Woodford, Imperial Innovations, the BIA and the London Stock Exchange have come together to bring you a ground breaking report that illustrates the fundamental truths about investing in the UK.

Hard facts, sound bite data and in depth case studies will reveal the state of the UK’s Healthcare & Life Sciences sectors, debunk the myths, assess the realities and address the challenges of healthcare investment in this country.

Why is this report needed?

The UK’s Healthcare and Life Science sectors need capital and development expertise that will allow them to demonstrate key financial markets. Too often, myths and misconceptions about the challenges, benefits and potential of returns on investment in the UK’s healthcare sectors has deterred the financial community from supporting the sector. This report will shine a light on the real truths about investing in the sector, showcase some case studies of genuine success stories and demonstrate the world class nature of the sector and that Healthcare and Life Sciences are mature, well-managed, investible sectors that have global reach and global presence.

Who is the report aimed at?

The report is targeted at the investment community and exposes the real state of the UK's Healthcare & Life Sciences sector. It provides, among other benefits:

 -  Hard facts, sound bite data and in depth case studies demonstrating how and where investors have made money from the sector
  -  A deep analysis of the myths, misconceptions and realities of investment in the sector
  -  Analysis of access to capital in the UK, including VC investment trends
  -  A comprehensive current market overview and assessment
  -  Investor insight from Neil Woodford
  -  Perspectives on the future of life science investment in the UK
  -  Analysis and conclusions on the attractiveness of UK healthcare opportunities

Who is contributing?

  • Rt. Hon. George Freeman MP - The future of UK Life Sciences
  • Nigel Pitchford, CIO, Imperial Innovations - The power of IP commercialisation businesses
  • Neil Woodford, Head of Investment, Woodford Investment Management - Is British Healthcare in good shape?
  • David MacMurchy, Partner, Head of Life Sciences, EY - Market overview and assessment
  • Chris Mayo, Consultant, Primary Markets, London Stock Exchange - UK listings: advantages, drivers and opportunities
  • Steve Bates, CEO, BIA - Is the eco-system in good health?
  • Elizabeth Klein, Founder, Klein-Edmonds Associates – Report Co-Author

Report and Event Enquiry

Download the Report here


Horizon Discovery is a UK Biotechnology company that combines deep scientific experience in translational research with a precision gene-editing platform incorporating rAAV, CRISPR and ZFN technologies.  The company provides custom cell line and in vivo model generation services for research and bioproduction applications, molecular reference standards, in vivo disease models, and contract research and screening services to over 1,000 organisations engaged in research; drug discovery and development; clinical diagnostics; and biopharmaceutical process optimization.  Horizon aspires to provide science-driven research solutions that lead to better understanding of the genetic basis of disease and better outcomes for patients, from sequence to treatment.


Clinigen Group is a blobal specialty pharmaceuticals and services business, supplying clinical trial, licensed and unlicensed critical, lifesaving drugs. Four distinct operating businesses which benefit from important synergies between them: Clinigen CTS – Global leader in the specialist supply and management of quality-assured medicines for patients in clinical trials; Idis MA – Global leader in ethical worldwide access to the most promising innovative early stage medicines on behalf of pharma and biotech companies to meet an unmet patient need; Idis GA – Ethical Supply of unlicensed or short supply medicines to patients via their physicians; Clinigen SP – SP acquires the rights to and then revitalises essential niche hospital only medicines and has a portfolio of oncology support and infectious disease medicines.

BTG is a growing international specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of liver tumours, advanced emphysema, severe blood clots and varicose veins, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today’s most complex healthcare challenges. To learn more about BTG, please visit:

Midatech is a nanomedicine company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with unmet medical need. Midatech is advancing a pipeline of novel clinical and pre-clinical product candidates based on its proprietary drug conjugate and sustained release delivery platforms with a clear focus on the key therapeutic areas of diabetes, cancer and neuroscience/ophthalmology. Midatech’s strategy is to develop its products in-house in rare cancers and with partners in other indications, and to accelerate growth of its business through strategic acquisition of complementary products and technologies.

Skyepharma combines proven scientific expertise with validated proprietary drug delivery technologies to develop innovative inhalation and oral pharmaceutical products.  The Group is eligible for revenues from 16 approved products in the areas of inhalation, oral, topical and injectable drug delivery, as well as generating income from the development of further products and technology licenses.  The products developed by the Group are marketed throughout the world by leading pharmaceutical companies. More than 50% of revenues are derived from products launched since March 2012, including flutiform®, Pacira’s EXPAREL® and the GSK Ellipta® range of products. The Group is investing in developing novel products and technologies to deliver additional growth. Skyepharma is listed on the London Stock Exchange (SKP). Its research and development is based in Muttenz, Switzerland. For more information, visit

Report Launch at Biotech and Money London 2016, 2-3 February

The report was exclusively launched at Biotech and Money’s flagship investment and partnering event on 2nd February, supported by a keynote panel assembled to discuss the themes. 


  -  Can the UK build a life science sector to rival that of the US? How?

  -  What are the catalysts and inhibitors?

  -  How can the lack of sources of capital and shortage of knowledgeable investors be addressed?
  -  What is the role of big pharma in capitalizing on the opportunity in the UK?

  -  How can incentives for investment be increased and the funding environment improved?

This 1hr session featured the cornerstone players of the report as well as key industry stakeholders to discuss the findings and highlights, plus debate the wider implications on the sector. The session was chaired by David MacMurchy of EY. There was also  exclusive pre-launch Investor breakfast from 8-9am at the Biotech and Money London conference.

Report panelists

Slide background

Report Supporters

Slide background